The weight loss drug market just had its biggest shakeup since Ozempic went viral. A new high-dose Wegovy approved days ago, oral pills replacing injections, and federal pricing deals slashing costs by 75% — the market in March 2026 looks nothing like it did a year ago.
If you're trying to figure out which GLP-1 medication is right for you, here's everything you need to know. For emerging research on how these drugs may slow aging itself, read our GLP-1 longevity explainer.
The Four Drugs at a Glance
| Drug | Active Ingredient | Approved For | Max Dose | Avg. Weight Loss | Monthly Cost (TrumpRx) |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 Diabetes | 2.0 mg injection | 6–7% | $350 |
| Wegovy | Semaglutide | Obesity / CV Risk | 2.4 mg injection | ~15% | $350 |
| Wegovy HD | Semaglutide | Severe Obesity | 7.2 mg injection | 20.7% | $350 |
| Wegovy Pill | Semaglutide | Obesity | 25–50 mg oral | ~16.6% | $150 |
| Mounjaro | Tirzepatide | Type 2 Diabetes | 15.0 mg injection | ~15–20% | $350 |
| Zepbound | Tirzepatide | Obesity / Sleep Apnea | 15.0 mg injection | 21–22% | $350 |
How They Actually Work
These drugs fall into two camps based on their mechanism:
- Targets the GLP-1 receptor only
- Mimics one gut hormone
- Proven cardiovascular benefits (SELECT trial — a key data point in GLP-1 longevity research)
- Now available as a daily pill
- Manufactured by Novo Nordisk
- Targets both GLP-1 and GIP receptors
- Dual hormone action = stronger appetite suppression
- Superior weight loss in head-to-head studies
- Injection only (for now)
- Manufactured by Eli Lilly
The dual-action approach of tirzepatide is why Zepbound and Mounjaro consistently edge out semaglutide drugs on raw weight loss numbers. But the gap is shrinking — Wegovy HD's 20.7% result nearly matches Zepbound's 21–22%.
Weight Loss: The Numbers That Matter
Average percent body weight loss in clinical trials over 68–72 weeks.
The Price Revolution
A year ago, these drugs cost $1,000–$1,350 per month without insurance. The November 2025 pricing agreement between the Trump administration, Novo Nordisk, and Eli Lilly changed everything.
- List price before deal: $1,060–$1,350/month
- TrumpRx cash price: $350/month for injectables, $150/month for oral Wegovy
- Medicare/Medicaid net price: $245/month (fixed)
- Medicare copay (starting July 2026): Capped at $50/month
- Where to buy: TrumpRx.gov bypasses pharmacy benefit managers entirely
The oral Wegovy pill at $150/month is the most affordable branded GLP-1 option on the market. For patients who hate needles and want to save money, it's the obvious entry point.
Who Should Take What?
- Choose Ozempic if you have Type 2 diabetes and want blood sugar control (weight loss is secondary)
- Choose Wegovy or Wegovy HD if weight loss is the primary goal and you want proven heart benefits
- Choose the Wegovy Pill if you want convenience, lower cost, and can't tolerate injections
- Choose Zepbound if you want maximum weight loss and don't mind injections
- Choose Mounjaro if you have Type 2 diabetes and want the strongest dual-action drug
- Ozempic won't deliver dramatic weight loss — it's a diabetes drug first
- Wegovy HD is brand new with limited real-world data at the 7.2 mg dose
- Wegovy Pill shows slightly less weight loss than the injectable version
- Zepbound has no cardiovascular outcome trial data yet (unlike Wegovy)
- Mounjaro is not FDA-approved for weight loss — insurance may deny coverage
The Timeline: What Got Us Here
What's Coming Next
The current four-drug race is about to become a six-drug race. Two pipeline drugs could reshape the market again:
CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, an amylin analog. Early trials project approximately 23% weight loss — beating everything currently available. The FDA decision is expected by October 2026.
Retatrutide (Eli Lilly) is the so-called "Triple G" agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. Late-stage trial results show up to 28.7% body weight loss — a number that would blow away every drug on this list. Approval is anticipated in 2027.
Medicare Coverage: The $170 Billion Bet
Historically, Medicare couldn't cover weight loss drugs — the Medicare Modernization Act of 2003 explicitly excluded them. The 2026 policy shift treats obesity as a chronic metabolic disease, not a lifestyle choice.
The Medicare GLP-1 Bridge program launches July 1, 2026, offering direct access with $50 monthly copays. By January 2027, the permanent BALANCE Model will transition coverage into standard Part D plans.
Federal officials estimate this coverage expansion could save $170 billion over time by reducing downstream costs from heart failure, kidney disease, and other obesity-related conditions. Scientists studying GLP-1s as longevity drugs suggest the savings could be even larger if anti-aging effects bear out.
The Bottom Line
For maximum weight loss in 2026, Zepbound still holds the crown — but Wegovy HD is now within striking distance. For affordability and convenience, the oral Wegovy Pill at $150/month changes the equation entirely. And if you're on Medicare, mark your calendar for July 1.
The drugs are getting stronger, cheaper, and more accessible. The question is no longer whether GLP-1 medications work — it's which one fits your body, your budget, and your goals.
